Enanta lands $43M NIAID development contract

Watertown, MA-based Enanta Pharmaceuticals reports that it has won a 5-year development contract with the National Institute of Allergy and Infectious Diseases (NIAID) which will provide up to $42.7 million to develop a "new class of bridged bicyclic antibiotics" known as Bicyclolides for the country's biodefense program. "Bicyclolide antibiotics discovered by Enanta offer a new broad spectrum approach to treating lethal infections, including those caused by biothreat pathogens," says CEO Jay Luly. "This contract will enable us to advance additional bicyclolide candidates into clinical development." Release

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.